drugset / Trial / NCT01902290

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility

NCT01902290

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if brodalumab (AMG 827) is safe and effective compared to placebo as measured by change in Asthma Control Questionnaire (ACQ) composite scores.

Timeline

Start
2013-05-22
Primary completion
2015-05-15
Completion
2015-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Brodalumab Monoclonal antibody 210 mg Subcutaneous

Indications